The FDA has accepted the new drug application for vericiguat for priority review. The sGC stimulator vericiguat is under development for the treatment of patients with chronic HF with ejection fraction <45%.

In HFrEF patients from the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin was similarly efficacious and safe in those receiving ARNI treatment and those not receiving ARNI treatment.

Two heart failure specialists from Glasgow, UK discuss a patient case to demonstrate that it can be difficult to diagnose HFpEF. They present tools that can help in the process of diagnosing HFpEF.

T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.

The Heart Failure Association of the ESC has recently published a position paper on SGLT2i therapy in heart failure, beyond glycemic control.

The American Heart Association has published a scientific statement covering diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM).

Using a case of a heart failure (HF) patient who was admitted to the hospital with acute decompensated HF (ADHF), two specialists discuss what the optimal treatment strategy in hospitalized patients should be during time of admission.

Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.

Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.

HFA Discoveries 2020 Despite promising preclinical findings and pathophysiologic rationale, the sGC stimulator praliciguat did not result in a difference in change in peak VO₂ compared to placebo in HFpEF patients.

HFA Discoveries These analyses of patient-reported outcomes in EMPERIAL trials suggest a trend towards reductions in HF symptom burden with empagliflozin compared to placebo in HFrEF patients.

HFA Discoveries An analysis of pooled data of the ATTR-ACT trial and a long-term extension study demonstrated reduction in mortality in ATTR-CM patients on 80 mg tafamidis compared to those on 20 mg.